Phase 2 Ovarian Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Women between 18 and 75 years of age at the time of enrollment
• People with a confirmed diagnosis (through tissue or cell testing) of high-grade serous or endometrioid ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, at an advanced stage (Stage III or IV)
• People whose cancer has been assessed by a specialist as unlikely to be fully removed with upfront surgery, or whose health makes immediate surgery too risky
• People whose cancer tests positive for HRD (a genetic marker related to DNA repair — confirm with trial site)
• People who have at least one measurable area of cancer visible on scans, meeting specific measurement standards
• People expected to survive at least 12 weeks
• People who are generally well enough to carry out light activity and care for themselves (a standard medical fitness score of 0 or 1)
• People whose blood counts, liver function, kidney function, and blood clotting results fall within specific healthy ranges when tested within one week before starting treatment (no blood support treatments allowed in the 14 days before that test)
• People whose heart scan shows the heart is pumping well (above a specific threshold), tested within 4 weeks before starting treatment
• People of childbearing potential who have a negative pregnancy test before starting, and who agree to use reliable contraception throughout the study
• People who are willing to join voluntarily, sign a consent form, follow the study requirements, and attend follow-up visits

Who may not be able to join:

• People whose ovarian, fallopian tube, or peritoneal cancer is not of the epithelial type (for example, germ cell tumors or borderline tumors)
• People who have previously received any cancer treatment, including chemotherapy, radiotherapy, surgery, targeted therapy, or immunotherapy (note: diagnostic procedures such as biopsy or laparoscopic staging may be permitted — confirm with trial site)
• People who have had another cancer diagnosis within the past 5 years, unless it was a fully cured, localised cancer such as certain skin cancers, early-stage bladder cancer, or pre-invasive breast or cervical conditions
• People who have taken part in another clinical drug trial or used an experimental drug within the 4 weeks before enrollment
• People who have received a live vaccine within 4 weeks before starting treatment, or who plan to receive one during the study
• People with a known allergy to any component of the trial treatment
• People with an active infection at the time of enrollment
• People with severe or uncontrolled illness of any kind
• People with active autoimmune diseases that have required systemic (whole-body) treatment within the past 2 years, or conditions considered at risk of returning — though some exceptions may apply (confirm with trial site)
• People who are pregnant, breastfeeding, or who return a positive pregnancy test before starting the study
• People whose doctor considers them to have serious health conditions that would make participation risky or difficult, including severely uncontrolled high blood pressure, heart problems such as heart attack or heart failure, serious irregular heartbeat, severe lung disease, severe diabetes, or active infections
• People with a documented history of neurological or psychiatric conditions, including epilepsy or dementia
• People who have previously received an organ transplant or stem cell transplant from a donor
• People with a known history of interstitial lung disease or non-infectious lung inflammation
• People with immune system deficiency, or who are currently taking steroid medications or other treatments that suppress the immune system
• People with conditions that increase the risk of bleeding, such as severe haemorrhoids, acute gastritis, or stomach ulcers
• People who have difficulty swallowing or who have a digestive condition that may affect how the body absorbs medication
• People considered by the treating doctor to be unsuitable for the study for any other reason

Important: Always verify eligibility with the trial site directly before applying.